Low-dose therapy for the control of infl ammation
Journal title PNEI REVIEW
Author/s Massimo Fioranelli, Paola Petrelli, Maria Grazia Roccia
Publishing Year 2017 Issue 2017/2
Language Italian Pages 12 P. 59-70 File size 1120 KB
DOI 10.3280/PNEI2017-002006
DOI is like a bar code for intellectual property: to have more infomation
click here
Below, you can see the article first page
If you want to buy this article in PDF format, you can do it, following the instructions to buy download credits
FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.
Low grade chronic inflammation (LGCI) is a very common condition; the incidence is proportional to age. Patients with chronic inflammatory disease have a higher risk of cardiovascular disease (CVD) and related mortality. Cardiovascular risk factors are of course a key factor for the onset of CVD; however, LGC acts independently: it accelerates atherosclerosis, favors myocardial infarction, cerebrovascular disease and heart failure (HF). Modulation of systemic system inflammation goes through various interventions: nutrition, exercise, microbiota control, stress modulation. A promising role is attributed to low-dose therapy that uses low doses of natural principles and biological molecules such as cytokines, neuropeptides, hormones and growth factors.
Keywords: Chronic inflammation, low-grade inflammation, cardiovascular diseases, microbiota, mitochondria, low-dose therapy
Massimo Fioranelli, Paola Petrelli, Maria Grazia Roccia, Terapia low-dose per il controllo dell’infi ammazione in "PNEI REVIEW" 2/2017, pp 59-70, DOI: 10.3280/PNEI2017-002006